Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

(2017) Delong Liu et al.   Journal of Hematology & Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

PD-1 checkpoint inhibition: Toxicities and management

(2017) Andrew W. Hahn et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

(2016) Archana Anantharaman et al.   BMC CANCER

Microsatellite Instability as a Biomarker for PD-1 Blockade

(2016) J. C. Dudley et al.   CLINICAL CANCER RESEARCH

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

(2016) Omar Abdel-Rahman   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

PD-1/PD-L1 blockade in renal cell cancer

(2016) Kathryn E. Beckermann et al.   Expert Review of Clinical Immunology

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

(2016) Bernhard Mlecnik et al.   IMMUNITY

Efficacy of PD-1 blockade in tumors with MMR deficiency

(2016) Valerie Lee et al.   Immunotherapy

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

CTC immune escape mediated by PD-L1

(2016) Xuefei Wang et al.   MEDICAL HYPOTHESES

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

(2016) C. Alix-Panabieres et al.   Cancer Discovery

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

(2016) Samit Chatterjee et al.   Oncotarget

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment

(2016) B. L. Khoo et al.   Science Advances

Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

(2016) Arun Satelli et al.   Scientific Reports

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

(2016) Chiara Nicolazzo et al.   Scientific Reports

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

Interferon-γ and tumor necrosis factor-α promote the ability of human placenta–derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4+interleukin-10+ and CD8+interleukin-10+Treg subsets

(2015) Heng Li et al.   CYTOTHERAPY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

(2015) Abhisek Swaika et al.   MOLECULAR IMMUNOLOGY

Frequent expression of PD-L1 on circulating breast cancer cells

(2015) Martine Mazel et al.   Molecular Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells

(2015) Joao Paulo Oliveira-Costa et al.   Oncotarget

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Peptide-based isolation of circulating tumor cells by magnetic nanoparticles

(2014) Linling Bai et al.   Journal of Materials Chemistry B

Evolution of end points for cancer immunotherapy trials

(2012) A. Hoos   ANNALS OF ONCOLOGY

Circulating Tumor Cells and Circulating Tumor DNA

(2011) Catherine Alix-Panabières et al.   Annual Review of Medicine